Novel fenofibric acid-loaded controlled release pellet bioequivalent to choline fenofibrate-loaded commercial product in beagle dogs

International Journal of Pharmaceutics

Volumn 490, Issue 1-2, 2015, Pages 273-280

  Kim, Kyung Soo ^a,b   Jin, Sung Giu ^a   Mustapha, Omer ^a   Yousaf, Abid Mehmood ^a   Kim, Dong Wuk ^a   Kim, Young Hun ^a,b   Kim, Jong Oh ^c   Yong, Chul Soon ^c   Woo, Jong Soo ^b   Choi, Han Gon ^a  

^a Hanyang University   (South Korea)

^b Hanmi Pharmaceutical Co Ltd   (South Korea)

^c Yeungnam University   (South Korea)

Author keywords

Bioavailability; Bioequivalence; Controlled release pellet; Dissolution; Fenofibric acid

Indexed keywords

CARRAGEENAN; CHOLINE FENOFIBRATE; DODECYL SULFATE SODIUM; ETHYL CELLULOSE; FENOFIBRATE; FENOFIBRIC ACID; GELATIN; MACROGOL 6000; MAGNESIUM CARBONATE; CHOLINE; DELAYED RELEASE FORMULATION; TABLET;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BEAGLE; BIOEQUIVALENCE; CANINE MODEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COATING; DRUG HALF LIFE; DRUG PELLET; DRUG SOLUBILITY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PELLET EXTRUSION; PH; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SPHERONIZATION; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; ANALOGS AND DERIVATIVES; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DELAYED RELEASE FORMULATION; DOG; PHARMACOKINETICS; SOLUBILITY; TABLET; THERAPEUTIC EQUIVALENCE;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CARRAGEENAN; CHOLINE; DELAYED-ACTION PREPARATIONS; DOGS; FENOFIBRATE; SOLUBILITY; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 84931273601     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.05.059     Document Type: Article

References (48)

1. S. Abdul, A.V. Chandewar, and S.B. Jaiswal A flexible technology for modified-release drugs: multiple-unit pellet system (MUPS) J. Controlled Release 147 2010 2 16
2. P. Alagona Jr. Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia J. Vasc. Health Risk Manage. 6 2010 351
3. J.A. Balfour, D. McTavish, and R.C. Heel Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia Drugs 40 1990 260 290
4. D. Bhavesh, and S. Shah Determination of fenofibric acid in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry: application to a bioequivalence study Biomed. Chromatogr. 23 2009 922 928
5. E. Bolcskei, G. Regdon Jr., T. Sovány, D. Ghanam, K. Knop, P. Kleinebudde, and K. Pintye-Hódi Preparing of pellets by extrusion/spheronization using different types of equipment and process conditions Drug Dev. Ind. Pharm. 40 2014 762 764
6. M. Bornhoft, M. Thommes, and P. Kleinebudde Preliminary assessment of carrageenan as excipient for extrusion/spheronisation Eur. J. Pharm. Biopharm. 59 2005 127 131
7. W.V. Brown Treatment of hypercholesterolaemia with fenofibrate: a review Curr. Med. Res. Opin. 11 1989 321 330
8. S.S. Chachad, M. Gole, G. Malhotra, and R. Naidu Comparison of pharmacokinetics of two fenofibrate tablet formulations in healthy human subjects Clin. Ther. 36 2014 967 973
9. D. Chanda, C.H. Lee, Y.H. Kim, J.R. Noh, D.K. Kim, J.H. Park, J.H. Hwang, M.R. Lee, K.H. Jeong, I.K. Lee, G.R. Kweon, M. Shong, G.T. Oh, J.Y. Chiang, and H.S. Choi Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner Hepatology 50 2009 880 892
10. K.H. Cho, and H.G. Choi Development of novel bepotastine salicylate salt bioequivalent to the commercial bepotastine besilate in beagle dogs Drug Dev. Ind. Pharm. 39 2013 901 908
11. K.H. Cho, Y.K. Choi, J.H. Kang, H.G. Choi, C.S. Yong, and Y.J. Park Development of a novel combination tablet containing trimebutine maleate and mosapride citrate for the treatment of functional dyspepsia Int. J. Pharm. 400 2010 145 152
12. G. Clarke, J. Newton, and M. Short Comparative gastrointestinal transit of pellet systems of varying density Int. J. Pharm. 114 1995 1 11
13. M. Davidson, R.S. Rosenson, K.C. Maki, S.J. Nicholls, C.M. Ballantyne, C. Setze, D.M. Carlson, and J. Stolzenbach Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial Cardiovasc. Drugs Ther. 26 2012 349 358
14. J.P. Dechesne, and L. Delattre A new enteric tablet of acetylsalicylic acid II. Biopharmaceutical aspects Int. J. Pharm. 34 1987 259 262
15. T.D. Filippatos, and M.S. Elisaf Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia Expert Opin. Pharmacother. 12 2011 1945 1958
16. A.L. Freed, S.B. Silbering, K.J. Kolodsick, D.T. Rossi, M. Mahjour, and C.A. Kingsmill The development and stability assessment of extemporaneous pediatric formulations of Accupril Int. J. Pharm. 304 2005 135 144
17. H.A. Garekani, A. Nokhodchi, M.A. Rayeni, and F. Sadeghi Preparation and characterization and release properties of Eudragit RS based ibuprofen pellets prepared by extrusion spheronization: effect of binder type and concentration Drug Dev. Ind. Pharm. 39 2013 1238 1246
18. E.I. Hamedelniel, J. Bajdik, P. Kása Jr., and K. Pintye-Hódi Study of the influence of alkalizing components on matrix pellets prepared by extrusion/spheronization Pharm. Dev. Technol. 17 2012 204 211
19. A. Hanafy, H. Spahn-Langguth, G. Vergnault, P. Grenier, M.T. Grozdanis, T. Lenhardt, and P. Langguth Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug Adv. Drug Deliv. Rev. 59 2007 419 426
20. G.M. Keating, and K.F. Croom Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus Drugs 67 2007 121 153
21. I. Khadra, Z. Zhou, C. Dunn, C.G. Wilson, and G. Halbert Statistical investigation of simulated intestinal fluid composition on the equilibrium solubility of biopharmaceutics classification system class II drugs Eur. J. Pharm. Sci. 67 2015 65 75
22. P. Kleinebudde Use of a power-consumption-controlled extruder in the development of pellet formulations J. Pharm. Sci. 84 1995 1259 1264
23. M. Koester, and M. Thommes New insights into the pelletization mechanism by extrusion/spheronization AAPS PharmSciTech 11 4 2010 1549 1551
24. M. Koester, E. Willemsen, C. Krueger, and M. Thommes Systematic evaluations regarding interparticular mass transfer in spheronization Int. J. Pharm. 431 2012 84 89
25. C. Krueger, and M. Thommes Multiple batch manufacturing of theophylline pellets using the wet-extrusion/spheronization process with κ-carrageenan as pelletisation aid Pharm. Dev. Technol. 18 2013 225 235
26. K. Lavanya, V. Senthil, and V. Rathi Pelletization technology: a quick review Int. J. Pharm. Sci. Res. 2 2011 1337 1355
27. H.T. Lim, P. Balakrishnan, D.H. Oh, K.H. Joe, Y.R. Kim, D.H. Hwang, Y.B. Lee, C.S. Yong, and H.G. Choi Development of novel sibutramine base-loaded solid dispersion with gelatin and HPMC: physicochemical characterization and pharmacokinetics in beagle dogs Int. J. Pharm. 397 2010 225 230
28. H. Ling, J.T. Luoma, and D. Hilleman A review of currently available fenofibrate and fenofibric acid formulations Cardiol. Res. 4 2013 47 55
29. A. Liu, A.D. Patterson, Z. Yang, X. Zhang, W. Liu, F. Qiu, H. Sun, K.W. Krausz, J.R. Idle, F.J. Gonzalez, and R. Dai Fenofibrate metabolism in the cynomolgus monkey using ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabolomics Drug Metab. Dispos. 37 2009 1157 1163
30. I. Locatelli, N. Nagelj Kovacic, A. Mrhar, and M. Bogataj Gastric emptying of non-disintegrating solid drug delivery systems in fasted state: relevance to drug dissolution Expert Opin. Drug Deliv. 7 2010 967 976
31. J.E. Noonan, A.J. Jenkins, J.X. Ma, A.C. Keech, J.J. Wang, and E.L. Lamoureux An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes Diabetes 62 2013 3968 3975
32. R.R. Panda, and A.K. Tiwary Hot melt granulation: a facile approach for monolithic osmotic release tablets Drug Dev. Ind. Pharm. 38 2012 447 461
33. Z.Z. Piao, K.H. Lee, D.J. Kim, H.G. Lee, J. Lee, K.T. Oh, and B.J. Lee Comparison of release-controlling efficiency of polymeric coating materials using matrix-type casted films and diffusion-controlled coated tablet AAPS PharmSciTech 11 2010 630 636
34. S.C. Porter, and C.H. Bruno 2nd ed. H.A. Liebermann, L. Lachman, J.B. Schwartz, Pharmaceutical Dosage Forms: Tablets Vol. 3 1990 Marcel Dekker New York 83 85
35. R.S. Rosenson Fenofibrate: treatment of hyperlipidemia and beyond Expert Rev. Cardiovasc. Ther. 6 2008 1319 1330
36. S. Sarkar, T.W. Wong, and C.V. Liew Importance of wet packability of component particles in pellet formation AAPS PharmSciTech 14 2013 1267 1277
37. C. Schmidt, and P. Kleinebndde Influence of the granulation step on coating pellets prepared by extrusion/spheronization Chem. Pharm. Bull. (Tokyo) 47 1999 405 412
38. R. Simo, and C. Hernandez Prevention and treatment of diabetic retinopathy: evidence from large, randomized trials. The emerging role of fenofibrate Rev. Recent Clin. Trials 7 2012 71 80
39. G. Steiner Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus Am. J. Cardiol. 102 2008 28L 33L
40. N. Tavakoli, M. Minaiyan, M. Tabbakhian, and Y. Pendar Preparation and evaluation of a controlled drug release of repaglinide through matrix pellets: in vitro and in vivo studies J. Microencapsul. 31 2014 529 534
41. M. Thommes, and P. Kleinebudde Use of kappa-carrageenan as alternative pelletisation aid to microcrystalline cellulose in extrusion/spheronisation. I. Influence of type and fraction of filler Eur. J. Pharm. Biopharm. 63 2006 59 67
42. V. Tsimihodimos, G. Miltiadous, S.S. Daskalopoulou, D.P. Mikhailidis, and M.S. Elisaf Fenofibrate: metabolic and pleiotropic effects Curr. Vasc. Pharmacol. 3 2005 87 98
43. F.J. Varum, H.A. Merchant, and A.W. Basit Oral modified-release formulations in motion: the relationship between gastrointestinal transit and drug absorption Int. J. Pharm. 395 2010 26 36
44. T.Y. Wong, R. Simo, and P. Mitchell Fenofibrate - a potential systemic treatment for diabetic retinopathy? Am. J. Ophthalmol. 154 2012 6 12
45. A.D. Wright, and P.M. Dodson Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies Eye (Lond.) 25 2011 843 849
46. D. Yadav, S. Survase, and N. Kumar Dual coating of swellable and rupturable polymers on glipizide loaded MCC pellets for pulsatile delivery: formulation design and in vitro evaluation Int. J. Pharm. 419 2011 121 130
47. X. Zhang, G. Chen, T. Zhang, Z. Ma, and B. Wu Effects of PEGylated lipid nanoparticles on the oral absorption of one BCS II drug: a mechanistic investigation Int. J. Nanomed. 9 2012 5503 5514
48. T. Zhu, J.C. Ansquer, M.T. Kelly, D.J. Sleep, and R.S. Pradhan Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans J. Clin. Pharmacol. 50 2010 914 921